NeuroVive First Day of Trading on NASDAQ OMX Stockholm

        Print
| Source: NeuroVive Pharmaceutical AB
Lund (Sweden) – April 10, 2013, NeuroVive Pharmaceutical AB (publ), a leading
mitochondrial medicine company, announces that its admission to NASDAQ OMX
Stockholm will become effective and trading of the shares will start at 09.00 am
(CET) today, 10th April 2013.

The stock will be listed as a Small Cap company within the Healthcare sector and
traded under the ticker symbol, NVP. No new shares have been issued in
conjunction with the listing on NASDAQ OMX Stockholm.

Mikael Bronnegard, CEO of NeuroVive Pharmaceutical (“NeuroVive”) said: “The
first day of trading on NASDAQ OMX Stockholm marks a new stage in our Company’s
evolution and demonstrates the continuing growth and development of the
business. Through this listing NeuroVive will gain international exposure within
life science, and increase its access to a broader and deeper pool of investors.
This will be crucial as we look to progress our product development programmes
and build on our leading position in mitochondrial medicine to create further
value for our shareholders.”

About NeuroVive Pharmaceutical AB (publ)
NeuroVive Pharmaceutical AB (www.neurovive.com), a leading mitochondrial
medicine company, is developing a portfolio of products to treat acute
cardiovascular and neurological conditions through mitochondrial protection.

NeuroVive´s products are based on development of cyclophilin inhibitors derived
from different chemistry platforms. The drugs work by preventing the death of
mitochondria in distressed cells and the subsequent cascade of intracellular
biochemical events that lead to secondary tissue damage following an acute
cardiac or traumatic brain injury.

NeuroVive’s lead product is CicloMulsion®, the first cyclophilin inhibitor for
the treatment of reperfusion injuries following cardiac stenting. CicloMulsion®
is currently in a 1000 patient Phase III clinical trial evaluating its ability
to reduce reperfusion injuries in patients with myocardial infarction.

NeuroVive is also developing NeuroSTAT®, a cyclophilin inhibitor, which is
entering a Phase IIa clinical trial in patients with severe traumatic brain
injury. Both indications have huge medical need and for which there are
currently no approved pharmaceutical treatment options. Both CicloMulsion® and
NeuroSTAT® are special formulations of cyclosporine for use in acute cardiac and
brain injury indications.

NeuroVive’s pipeline includes novel cyclophilin inhibitors, and drug candidates
that act on mitochondria to address energy regulation disorders.


Media and investor relations contacts
NeuroVive Pharmaceutical: Mikael Bronnegard
Email: info@neurovive.com
Phone No: +46 (0) 70 299 62 64

Citigate Dewe Rogerson: Nina Enegren / David Dible
Email: nina.enegren@citigatedr.co.uk
Phone No: +44 207 282 1050